Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance

Group 1 - Conduit Pharmaceuticals Inc. has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, allowing its securities to continue being listed and traded on The Nasdaq Stock Market [1][6] - The Nasdaq Hearing Panel has imposed a Discretionary Panel Monitor for one year starting from May 15, 2025, to ensure long-term compliance with continued listing requirements [2] - Conduit operates as a multi-asset clinical stage life science company, focusing on an efficient model for compound development, utilizing artificial intelligence and cybernetics [3]